Generic name: lithium carbonate
Dosage form: tablet, film coated, extended release
This dosage information does not include all the information needed to use Lithobid safely and effectively. See full prescribing information for Lithobid.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Optimal patient response can usually be established with 1800 mg/day in the following dosages:
1Can also be administered on 600 mg TID recommended dosing interval.
|LITHOBID®||3 tabs||3 tabs|
|Extended-Release Tablets1||(900 mg)||(900 mg)|
Such doses will normally produce an effective serum lithium concentration ranging between 1.0 and 1.5 mEq/L. Dosage must be individualized according to serum concentrations and clinical response. Regular monitoring of the patient's clinical state and of serum lithium concentrations is necessary. Serum concentrations should be determined twice per week during the acute phase, and until the serum concentrations and clinical condition of the patient have been stabilized.
Desirable serum lithium concentrations are 0.6 to 1.2 mEq/L which can usually be achieved with 900-1200 mg/day. Dosage will vary from one individual to another, but generally the following dosages will maintain this concentration:
1Can be administered on TID recommended dosing interval up to 1200 mg/day.
|LITHOBID®||2 tabs||2 tabs|
|Extended-Release Tablets1||(600 mg)||(600 mg)|
Serum lithium concentrations in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months. Patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations of 1.0 to 1.5 mEq/L. Geriatric patients often respond to reduced dosage, and may exhibit signs of toxicity at serum concentrations ordinarily tolerated by other patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
- Blood samples for serum lithium determinations should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8-12 hours after previous dose). Total reliance must not be placed on serum concentrations alone. Accurate patient evaluation requires both clinical and laboratory analysis.
- LITHOBID® Extended-Release Tablets must be swallowed whole and never chewed or crushed.